Welcome to our dedicated page for Thermo Fisher Scientific news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fisher Scientific stock.
Thermo Fisher Scientific, Inc. (TMO) is a global leader in providing science-based solutions, offering a wide range of products and services in the life sciences, analytical instruments, specialty diagnostics, and laboratory products sectors. The company's expansive portfolio includes scientific instruments, laboratory equipment, diagnostic consumables, and life science reagents, serving customers both in the United States and internationally.
Thermo Fisher operates through four distinct segments as of end-2023:
- Analytical Technologies (17% of sales): This segment focuses on providing high-quality instruments and software solutions for various scientific applications.
- Specialty Diagnostic Products (10% of sales): This segment specializes in offering diagnostic reagents and instruments for medical and research laboratories.
- Life Science Solutions (23% of sales): This segment provides reagents, instruments, and consumables used in biological research and drug development.
- Lab Products and Services (54% of sales): This is the largest segment, encompassing laboratory supplies, equipment, and contract research organization (CRO) services.
Thermo Fisher is continually expanding its offerings and capabilities through strategic partnerships, acquisitions, and technological innovation. The company's robust financial performance underscores its leadership in the industry, driven by consistent revenue growth, strong market presence, and a commitment to advancing scientific research and healthcare.
Recent achievements include technological advancements in analytical instruments, enhanced diagnostic solutions, and expanded biopharma services, reflecting Thermo Fisher's dedication to supporting life-saving research and diagnostic processes. Thermo Fisher remains committed to delivering high-quality products and services, fostering scientific breakthroughs, and maintaining its position at the forefront of scientific innovation.
Thermo Fisher Scientific reported strong second quarter results for 2022, with revenue reaching $10.97 billion, marking an 18% increase. The company achieved GAAP diluted EPS of $4.22 and adjusted EPS of $5.51. Core organic revenue growth was 13%, supported by $0.63 billion in COVID-19 testing revenue. Significant product launches included the Gibco CTS TrueCut Cas9 Protein and the Phadia 2500+ series. The company expanded its production capacity to meet rising demand in high-growth markets, contributing to a strong performance outlook.
Mercy BioAnalytics has appointed Dr. Dawn Mattoon as Chief Operating Officer, effective immediately. With a 20-year career in biotechnology, Dr. Mattoon previously led Clinical Diagnostics at Quanterix Corporation, overseeing the launch of COVID-19 tests and securing FDA Breakthrough Device designations for Alzheimer's and Multiple Sclerosis diagnostics. Her expertise will bolster Mercy's efforts in commercializing the Mercy Halo™ early cancer detection platform, which targets hard-to-detect ovarian and lung cancers. CEO Paul Blavin expressed optimism for growth under her leadership.
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a quarterly cash dividend of $0.30 per share, approved by its Board of Directors on July 7, 2022. The dividend is set to be paid on October 14, 2022, to shareholders on record as of September 15, 2022. With annual revenues around $40 billion, Thermo Fisher continues to support scientific progress through innovative technologies and services.
Thermo Fisher Scientific Inc. (NYSE: TMO) will release its financial results for Q2 2022 on
The company reported an annual revenue of approximately
Relation Therapeutics has successfully raised
Dr.
Thermo Fisher Scientific (NYSE:TMO) has unveiled new mass spectrometry instruments, workflows, and software at the 70th ASMS Conference from June 5-9, 2022, in Minneapolis. These innovations aim to enhance analytical insights and accelerate biopharma development. Notable products include the Thermo Scientific Direct Mass Technology and the AccelerOme Automated Sample Preparation Platform, designed to improve reproducibility and detail in biotherapeutic analysis. Additionally, cross-industry collaboration with TransMIT GmbH aims to enhance spatial multi-omics applications.
Thermo Fisher Scientific (NYSE:TMO) released its annual Corporate Social Responsibility report, emphasizing progress in environmental, social, and governance (ESG) objectives. Key highlights include a 12% reduction in Scope 1 and 2 emissions since 2018, commitment to net-zero emissions by 2050, and an increase in spending with underrepresented businesses from
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a quarterly cash dividend of $0.30 per common share on May 18, 2022. The dividend will be payable on July 15, 2022, to shareholders of record as of June 15, 2022. The company, a leading name in serving science, reported an annual revenue of approximately $40 billion. Thermo Fisher aims to enhance health, safety, and environment through its extensive range of innovative technologies and services.
Thermo Fisher Scientific Inc. (NYSE: TMO) announced that its CEO, Marc N. Casper, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 12:20 p.m. EDT. The presentation will be accessible via a webcast on the company's Investor Relations page. Thermo Fisher Scientific reported annual revenues of approximately $40 billion, focusing on making the world healthier, cleaner, and safer through innovative technologies and pharmaceutical services. For more details, visit www.thermofisher.com.
Thermo Fisher Scientific reported first-quarter 2022 revenue of $11.82 billion, achieving 19% growth year-over-year. The company's GAAP diluted EPS was $5.61, down from $5.88 in Q1 2021, while adjusted EPS rose to $7.25. The results highlighted 16% core organic growth and $1.68 billion from COVID-19 testing. The launch of innovative products and a 15-year collaboration with Moderna for mRNA vaccine manufacturing were key highlights. The company also repurchased $2.0 billion in stock and increased its dividend by 15%.
FAQ
What is the current stock price of Thermo Fisher Scientific (TMO)?
What is the market cap of Thermo Fisher Scientific (TMO)?
What does Thermo Fisher Scientific, Inc. specialize in?
What are the main segments of Thermo Fisher Scientific?
How much of Thermo Fisher's sales come from Lab Products and Services?
Where does Thermo Fisher Scientific operate?
What recent achievements has Thermo Fisher Scientific made?
What is Thermo Fisher Scientific's stock symbol?
How does Thermo Fisher Scientific support scientific research?
What types of products does Thermo Fisher Scientific offer?
What is Thermo Fisher's commitment to the healthcare industry?
What sets Thermo Fisher Scientific apart in its industry?
